• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular Therapeutix’s ophthalmic device gains Medicare coverage early

July 26, 2019 By Nancy Crotti

Ocular TherapeutixOcular Therapeutix logo (NSDQ:OCUL) said today that the Centers for Medicare and Medicaid Services has assigned a specific and permanent reimbursement J-code for its Dextenza ophthalmic insert, which is approved for the treatment of ocular inflammation and pain following ophthalmic surgery.

The code assigned to Dextenza through the Healthcare Common Procedure Coding System will become effective on October 1, 2019.

Dextenza is designed to deliver drugs for up to 30 days following treatment in a physician’s office. The Bedford, Mass.-based company is positioning its product as a way to eliminate the current standard of care for post-surgical pain – topical steroid eye drops.

“We are pleased that CMS has issued a unique J-code for Dextenza, and has done so one full quarter earlier than expected,” said Ocular Therapeutics’ president & CEO Antony Mattessich in a news release. “Issuance of the J-code is important for the company as it now enables reimbursement in the office setting as well as in the surgical center, providing increased flexibility to physicians on how they use the product. We anticipate that having a J-code assigned will facilitate reimbursement of and increase access to our product and will give us the opportunity to expand the target market of Dextenza to commercial insurers.”

OCUL stock was up nearly 13% to $4.93 per share in midday trading.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Pain Management, Uncategorized, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), Ocular Therapeutix

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS